How to improve vaccine procurement strategies to optimise coverage in Europe

How to improve vaccine procurement strategies to optimise coverage in Europe

Tim Wilsdon, Ryan Lawlor
Life Sciences

Vaccination programmes implemented across Europe play a central role in the prevention and spread of serious infectious diseases and have brought significant benefits to both patients and clinicians. With the ongoing COVID-19 pandemic and the global focus on developing a vaccine, the importance of government-sponsored vaccination programmes is clearer than ever.

There are a variety of models used to procure vaccines for large-scale immunisation programmes, governed by the European legal framework for procurement. These range from price-based models, designed to acquire vaccines at the lowest cost possible, to value-based models that focus on a drug’s perceived value to clinicians, patients and healthcare systems. Price-based models are popular in many countries as they result in lower costs in the short term. However, as Tim Wilsdon and Ryan Lawlor explain, a recent analysis indicates that a price-based vaccine procurement model can limit the long-term effectiveness and sustainability of many vaccination programmes and potentially put public health at risk.

To read the article in European Pharmaceutical Review, click here.